Equinox Gold Corp. Common Shares vs Twist Bioscience Corp — how do they compare? Equinox Gold Corp. Common Shares trades at $11.36 (market cap $12.92B), while Twist Bioscience Corp trades at $154.5 (market cap $10.08B). The key difference: Equinox Gold Corp. Common Shares is the larger of the two by market cap, and Equinox Gold Corp. Common Shares pays a 0.47% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinox Gold Corp. Common Shares for 0 Days and Twist Bioscience Corp for 27 Days on average.
| EQX | TWST | |
|---|---|---|
Market Cap | $12.92B | $10.08B |
Volume | 9,067,677 | 4,229,037 |
Sector | Basic Materials | Health |
52-Week High | $18.76 | $205.00 |
52-Week Low | $8.62 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $13.02B | $10.01B |
Dividend Yield | 0.47% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Equinox Gold is a gold mining company with operations in the Americas. It produces gold and develops additional mining projects.
Read more on EQX →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →